Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Phenobarbital in Neonatal Seizures
NCT04320940Phase 3Terminated
- Sponsor
- NEMA Research
- Start
- Mar 2021
- Primary completion
- Feb 2023
- Modality
- Allosteric Modulators
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of phenobarbital in neonatal seizures (2 arms), sponsored by NEMA Research. Primary endpoint: Neonates Who do Not Require Additional Seizure Treatment After the First Dose of Phenobarbital at 24 hours. Started Mar 2021; status: terminated.
02
Drugs
phenobarbital
03
Conditions
neonatal seizures
Beyond the preview
Go deeper on NCT04320940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04320940.